Skip to main content
AARTIDRUGS · Health Care · 2026-08-07

Aarti Drugs Ltd

MARKET: BULL TOPPING · 2026-08-07
₹416.2
+1.30% today
₹3,799 Cr · Small cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. The company was incorporated in 1984 and is headquartered in Mumbai, India.

Visit company website →
P/E (TTM)
18.3
Forward 14.8
Earnings Growth (YoY)
-12.0%
Revenue +6.4%
ROE
+13.4%
Profit margin +7.6%
Dividend Yield
0.51%
P/B 2.3
vs 52W High
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 18
1w13w26w
Week 18 — proven structure, sweet spot
How long this stock has been basing. Longer bases can produce stronger breakouts — but don't anticipate, wait for the breakout.
vs 200 DMA
Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.
Rel Volume
0.50x
vs 50-day avg
Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.
Trend Health
MA20 trending up · +3.5% vs MA50 +3.2%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
51.6%
20d Δ
+1.6pp
1M return
+3.1%
3M return
+11.6%
Sector Stage-2 % · last 20 days
Sector has 79 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
→ Flat
Stage 2%
50.5%
20d Δ
+0.5pp
1M return
+1.9%
3M return
+11.7%
Industry Stage-2 % · last 20 days
Industry has 53 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2026-04-02 → 2026-08-07
S? 18w
2026-04-022026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 18w current
Total tracked: 18 weeks across 1 stage run.
1M
+5.3%
3M
+7.3%
6M
YTD
1Y
Scan Membership
Not in any current scan.
Recent Stage Timeline
2026-08-07S
Wk 18 · Vol x
2026-08-06S
Wk 18 · Vol x
2026-08-05S
Wk 17 · Vol x
2026-08-04S
Wk 17 · Vol x
2026-08-03S
Wk 17 · Vol x
2026-07-31S
Wk 17 · Vol x
2026-07-30S
Wk 17 · Vol x
2026-07-29S
Wk 16 · Vol x
2026-07-28S
Wk 16 · Vol x
2026-07-27S
Wk 16 · Vol x
2026-07-24S
Wk 16 · Vol x
2026-07-23S
Wk 16 · Vol x
Sector Peers — Stage 2All →
DIVISLAB
wk 12 · -3.6% from hi
8.5
LAURUSLABS
wk 16 · -0.3% from hi
8.4
PPLPHARMA
wk 4 · 0.0% from hi
8.2
LALPATHLAB
wk 9 · 0.0% from hi
7.9
SHILPAMED
wk 13 · 0.0% from hi
7.8
Moving averages & range
50 DMA
₹391.8
200 DMA
52W High
52W Low
5D Low
₹407.3
Resistance levels (recent highs)
20d High
₹426.9
60d High
₹426.9
120d High
250d High
Next resistance
+2.6%
to 20d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.